SCHEMBL2736622

SCHEMBL2736622

Cn1c2c(cc(C=O)c1=O)CCCC2

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CNR2 P34972 14/20 0.36
CNR1 P21554 10/20 0.36
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
RXFP1 Q9HBX9 1/20 0.33
MYC P01106 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL217768 0.77 CNR2 (0.60) CNR2CNR1ALDH1A1
SCHEMBL13716013 0.76 CNR2 (0.62) CNR2CNR1
SCHEMBL5540993 0.73 CNR2 (0.48) CNR2CNR1BRD4CREBBP
SCHEMBL2736618 0.71 CNR2 (0.41) CNR2CNR1MAPTBRD4CREBBP
SCHEMBL26088619 0.71 CNR2 (0.47) CNR2CNR1ALDH1A1HPGD
SCHEMBL2736907 0.70 CNR2 (0.49) MEN1KMT2ACNR2CNR1ALDH1A1
SCHEMBL26089078 0.70 CNR2 (0.49) MEN1KMT2ACNR2CNR1ALDH1A1
SCHEMBL13990928 0.69 CNR2 (0.47) KMT2ACNR2CNR1ALDH1A1HPGD
SCHEMBL2736603 0.69 BRPF1 (0.40) CNR2CNR1
SCHEMBL14215376 0.69 CNR2 (0.42) CNR2CNR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027144-A1 Novel use of cannabinoid receptor agonist CNR2, CNR1, OPRM1 MEN1 4737/4885KMT2A 2110/4885CNR2 1/4885
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R MEN1 3159/4885KMT2A 2963/4885CNR2 1/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 MEN1 4507/4885KMT2A 2819/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.